Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances

Overview

Journal Cardiol Clin

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 17

PMID 39551565

Authors

Ashley F Stein-Merlob

Rachel Swier

Darko Vucicevic

Affiliations

Soon will be listed here.

Abstract

Diagnosis and treatment of cardiac amyloidosis have rapidly evolved over the past decade by harnessing mechanisms of disease pathogenesis. Cardiac amyloidosis is caused by myocardial deposition of fibrils formed by misfolded proteins, namely transthyretin (ATTR) and immunoglobulin light chains (AL). Advances in noninvasive imaging have revolutionized diagnosis of ATTR cardiomyopathy (CM). Novel treatments for ATTR-CM utilize a range of therapeutic techniques, including protein stabilizers, interfering RNA, gene editing, and monoclonal antibodies. AL-CM, primarily driven by plasma cell dyscrasias, requires treatment with chemotherapy and consideration for autologous stem cell transplant. These incredible advances aim to improve patient outcomes in cardiac amyloidosis.

References

Saelices L, Chung K, Lee J, Cohn W, Whitelegge J, Benson M . Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc Natl Acad Sci U S A. 2018; 115(29):E6741-E6750. PMC: 6055172. DOI: 10.1073/pnas.1805131115. View

Lee C, Nayak A, Sethuraman A, Belfort G, McRae G . A three-stage kinetic model of amyloid fibrillation. Biophys J. 2007; 92(10):3448-58. PMC: 1853138. DOI: 10.1529/biophysj.106.098608. View

Bazoukis G, Saplaouras A, Efthymiou P, Yiannikourides A, Liu T, Sfairopoulos D . Atrial fibrillation in the setting of cardiac amyloidosis - A review of the literature. J Cardiol. 2024; 84(3):155-160. DOI: 10.1016/j.jjcc.2024.03.008. View

Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

Falk R, Alexander K, Liao R, Dorbala S . AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12):1323-41. DOI: 10.1016/j.jacc.2016.06.053. View

Duffy G, Cheng P, Yuan N, He B, Kwan A, Shun-Shin M . High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiol. 2022; 7(4):386-395. PMC: 9008505. DOI: 10.1001/jamacardio.2021.6059. View

Cappelli F, Tini G, Russo D, Emdin M, Del Franco A, Vergaro G . Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid. 2020; 28(1):12-18. DOI: 10.1080/13506129.2020.1798922. View

Karlstedt E, Jimenez-Zepeda V, Howlett J, White J, Fine N . Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. J Card Fail. 2019; 25(3):147-153. DOI: 10.1016/j.cardfail.2019.01.006. View

Merlini G, Dispenzieri A, Sanchorawala V, Schonland S, Palladini G, Hawkins P . Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018; 4(1):38. DOI: 10.1038/s41572-018-0034-3. View

10.

Muchtar E, Gertz M, Kyle R, Lacy M, Dingli D, Leung N . A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clin Proc. 2019; 94(3):472-483. DOI: 10.1016/j.mayocp.2018.08.006. View

11.

Hammarstrom P, Schneider F, Kelly J . Trans-suppression of misfolding in an amyloid disease. Science. 2001; 293(5539):2459-62. DOI: 10.1126/science.1062245. View

12.

Maurer M, Kale P, Fontana M, Berk J, Grogan M, Gustafsson F . Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023; 389(17):1553-1565. PMC: 10757426. DOI: 10.1056/NEJMoa2300757. View

13.

Treibel T, Fontana M, Gilbertson J, Castelletti S, White S, Scully P . Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016; 9(8). DOI: 10.1161/CIRCIMAGING.116.005066. View

14.

Fontana M, Berk J, Gillmore J, Witteles R, Grogan M, Drachman B . Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2024; 392(1):33-44. DOI: 10.1056/NEJMoa2409134. View

15.

Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J . Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun. 2021; 12(1):2726. PMC: 8113484. DOI: 10.1038/s41467-021-22877-8. View

16.

Magalhaes J, Saraiva M . Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol. 2011; 70(12):1097-106. DOI: 10.1097/NEN.0b013e31823a44f4. View

17.

Rapezzi C, Fontana M . Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis: Is it Just Amyloid Infiltration?. JACC Cardiovasc Imaging. 2018; 12(7 Pt 1):1174-1176. DOI: 10.1016/j.jcmg.2018.07.007. View

18.

Chao C, Jeong J, Arsanjani R, Kim K, Tsai Y, Yu W . Echocardiography-Based Deep Learning Model to Differentiate Constrictive Pericarditis and Restrictive Cardiomyopathy. JACC Cardiovasc Imaging. 2023; 17(4):349-360. DOI: 10.1016/j.jcmg.2023.09.011. View

19.

Adams D, Tournev I, Taylor M, Coelho T, Plante-Bordeneuve V, Berk J . Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022; 30(1):1-9. DOI: 10.1080/13506129.2022.2091985. View

20.

Mangione P, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S . Plasminogen activation triggers transthyretin amyloidogenesis . J Biol Chem. 2018; 293(37):14192-14199. PMC: 6139548. DOI: 10.1074/jbc.RA118.003990. View